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Warming ratesA novel, aseptic closed system vitriﬁcation (VTF) technique for the cryopreservation of embryos and
oocytes has been developed and clinically validated in this study. It combines the practicality of
embryo-containing sterile ﬂexipettes stored safely and securely with 0.3 ml CBS™ embryo straws pos-
sessing weld seals. The cooling and warming rates of this double container system were determined
using a data logger. Upon direct plunging into LN2, the ﬂexipettes cool at an average rate of
1391 C/min, while warming occurs at an average rate of 6233 C/min in a 37 C 0.5 M sucrose bath.
Direct deposition of the ﬂexipette into a warming bath insured a rapid transition between 100 and
60 C to minimize potentially harmful recrystalization associated with devitriﬁcation. In conclusion,
the lS-VTF system has exhibited higher (p < 0.05) intact survival, implantation and live birth rates than
conventional slow freezing methods. The effective embryo transfer of vitriﬁed blastocysts proved similar
to or better than fresh embryo transfer outcomes. The sustained clinical use of lS-VTF has justiﬁed a
change in our infertility practice.
Capsule: The microSecure vitriﬁcation (lS-VTF) procedure is a low-cost, non-commercial, aseptic,
closed system that offers technical simplicity and repeatability, while effectively attaining an estimated
4:1 warming-to-cooling rate ratio, which supports excellent embryo survival and sustained viability.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The development and use of open system vitriﬁcation devices in
the 21st century proved highly effective at achieving ultra-rapid
cooling rates (e.g., >10–20,000 C/min), and maintaining human
embryo and oocyte viability [5,6,16,17,22,23]. Early success led
to the commercial development of numerous high-cost commer-
cial vitriﬁcation devices for use in the IVF industry. These devices
typically require technical precision and experience to pipette
embryos or oocytes in micro-volumes (1 ll or less) onto a sec-
ondary device surface. The further reduction of residual volume
around the embryo(s)/oocyte(s) represents another variable, but
critical, step that allows for maximum cooling and warming rates
to be achieved. By striving for ultra-rapid cooling rates, these open
system devices are highly dependent on attaining ultra-rapid
warming rates to optimize survival of oocytes [21,25].Conversely, closed devices, which necessarily involve cooling and
warming at lower rates, are dependent on the use of a higher intra-
cellular concentration of permeating cryoprotectants to avoid ice
formation and achieve high survival rates [30,35]. Therefore, closed
devices are more tolerant of slower warming rates to minimize
recrystalization events [36]. In both cases, survival is dependent
on warming rates and optimized when warming rates exceeded
cooling rates to minimize potentially lethal recrystallization events
[10–12,29].
In a decade of escalated concern and awareness regarding good
tissue handling practices (GTPs), FDA regulations and European
Union directives, cryopreservation methods that emphasize
secure/aseptic storage, technical ease/repeatability, and consistent
outcomes are desirable. Variability in the successful application of
commercial vitriﬁcation device procedures is attributed to ‘‘techni-
cal signature’’, i.e., variation in technical skill between programs
and individuals [38]. Ideally, a universal vitriﬁcation device for
blastocysts that insures technical simplicity, safety and repeatabil-
ity while routinely achieving high recovery, survival and viability
rates post-warming is needed in the assisted reproductive technol-
ogy industry. Although viral cross-contamination between human
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[7,28], the potential exposure of samples in open devices to various
common environmental pathogens (e.g., bacteria, fungi, myco-
plasma) in non-sterilized LN2 creates an undesirable exposure risk
for any laboratory [4]. The use of aseptic, closed vitriﬁcation
devices provides the most reasonable alternative to the safe and
secure storage of vitriﬁed gametes and embryos, without having
to resort to laborious, costly and impractical decontamination
and LN2 sterilization procedures [4,26,27]. It is worth mentioning
that viral cross-contamination of bovine embryos with BVBD and
BHV-I, as well as bacteria, has occurred under experimental condi-
tions [3], but that those same types of harmful pathogen have also
been effectively controlled in validation studies by CryoBioSystems
with their patented ionomeric resin plastic straws which reliably
weld seals. Considering that comparative trials between open
and closed vitriﬁcation devices have exhibited no difference in
embryo survival rates or pregnancy outcomes [18,19,24,25], it is
puzzling why the ART industry dogma regarding the importance
of ultra-rapid cooling rates persists [36].
A novel, aseptic vitriﬁcation technique called microSecure vitri-
ﬁcation (lS-VTF) was previously validated in the mouse model
[32,34], offering technical ease, reliability and cryo-security using
two FDA compliant devices. This low-cost, non-commercial vitriﬁ-
cation system offered numerous other quality control advantages
including a unique tamperproof and internalized dual-colored
labeling system [33]. A series of preliminary mouse embryo inves-
tigations documented the promising potential of lS-VTF [32],
while achieving cooling rates >1100 C/min and a suboptimal,
biphasic warming rate pattern under ambient conditions. The
objectives of our four phase validation study was to document
the cryophysics of a modiﬁed warming protocol and verify the
overall clinical efﬁcacy of the lS-VTF procedure in contrast to stan-
dard slow freezing protocols.
Materials and methods
In our development of the lS-VTF procedure, we obtained IRB
approval (Coastal IRB 2008, and Aspire IRB 2009–2012) to conduct
a ‘‘Comparative Human Oocyte Cryopreservation’’ study.
Investigations began with a series of preliminary validation and
veriﬁcation studies on discarded human immature oocytes that
were matured in vitro and abnormal fertilized embryos of
various stages (e.g., zygotes, cleavage and blastocysts) to assess
the efﬁcacy of lS-VTF using Me2SO-free S3/Innovative Cryo
Enterprises LLC (I.C.E.) solutions [38]. The basic composition of
these Hepes-buffered sterile aqueous solutions includes organic
and inorganic salts, non-essential/essential amino acids and
human serum albumin. Ethylene glycol, ﬁcoll and sucrose were
added to the Oocyte and Embryo I.C.E. vitriﬁcation solutions, while
glycerol was supplemented to the blastocyst solutions. The exact
concentrations of glycol- or glycerol-based cryoprotectants in the
oocyte, embryo and blastocyst solutions, respectively, as well as
the content of albumin and other macromolecules in the I.C.E.
solutions are proprietary commercial properties and have not been
disclosed. However, the approximate total content of permeable
cryoprotective agents (CPAs) in the ﬁnal blastocyst vitriﬁcation
solution is 7.9 M, while the Oocyte solution is 3.6 M with an
appreciable amount of non-permeating CPAs. These solutions are
readily available for use through I.C.E. (Linden, NJ) for replication
of study results.
lS-VTF apparatus
The lS-VTF method combines the use of 300 lm ID sterile ﬂex-
ipettes (Cook Medical, Bloomington, IN) to load vitriﬁcation solu-
tions with oocytes or embryos before placing the dried ﬂexipetteinto a 0.3 ml CBS™ embryo straw with an internalized hydropho-
bic plug (CryoBioSystems; Irvine Sci., Santa Ana, CA) for secure,
long-term aseptic storage in LN2. In brief, ﬂexipettes that are rou-
tinely used in embryology laboratories worldwide are individually
extracted from their sterile container and shortened approximately
3 cm from the base and then securely placed onto a Stripper pipet-
tor (preset to 3 ll). Individual colored labels (1.300  0.500; CL-23, GA
International Inc.) were then created, adhered to a 40 mm color
coded, weighted ID rod and inserted into the internal labeling
end of the CBS™ straw, before being weld sealed under ambient
conditions using a Syms 1 sealer (CryoBioSystems), which elimi-
nates technical variation.
Cooling and warming rate determination
The validation of cooling and warming rates (Phase 1) was
determined using a DATAQ Instruments Model DI-1000-USB data
logger (www.dataq.com) and an Omega 5SRTC-TT-T-30-36 ﬁne
(0.13 mm diameter) thermocouple. The thermocouple was
threaded into the base of the ﬂexipette ﬁlled with 3 ll of I.C.E. vit-
riﬁcation solution (n = 4), and the ﬂexipette was then inserted into
a 0.3 ml CBS straw, which was then plunged into LN2 for tempera-
ture tracking at 0.2 s intervals. Similar measurements were also
taken upon warming, but for warming, the extracted ﬂexipette
was immediately allowed to warm in ambient air (preliminary
study, Fig. 1) or plunged into a 37 C solution within a 58 mm petri
dish (Figs. 2C and 3). All data points were plotted using SigmaPlot,
and mean cooling and warming rates were calculated for each run
between 0 and 125 C and averaged over four independent runs.
Embryo culture and viability testing
All oocytes and embryos were cultured in Global medium
(LifeGlobal, Guilford, CT; 25 ll droplets under oil) using tri-gas
mini Sanyo/Panasonic MCO-5 M incubators (5% O2 and 5.3–6.1%
CO2) at 37 C under humidiﬁed conditions. All mature oocytes
were inseminated by intracytoplasmic sperm injection (ICSI)
[31], and their fertilization status determined 16–21 h post-ICSI.
Normal 2PN zygotes were maintained in extended culture for up
to 6 days to promote blastocyst formation, with fresh embryo
transfer performed on day 5 and residual fair to good quality blas-
tocysts cryopreserved on days 5 or 6. In vitro matured oocytes and
abnormally fertilized zygotes (1PN or 3PN) from consenting
patients were assigned to vitriﬁcation treatment as oocytes
(n = 21), zygotes (n = 43), cleaved embryos (n = 28) or blastocysts
(n = 39), which may have involved extended culture in research
dishes, as described above. Their survival was subsequently
assessed in Phase 2 of the validation process.
Prior to implementing vitriﬁcation into our clinical practice in
November 2008, conventional slow freezing was performed with-
out pre-freeze blastocoele collapse (BL-SF; prior to November
2007) [13,15] or with induced-collapse (CBL/SF; November 2007
thru December 2008) by single pulse laser ablation of a trophecto-
dermal cell using a ZILOS-tk infrared laser (Hamilton-Throne,
Beverly, MA). Conventional BL-SF involved a 5 min equilibration
in a PBS stock solution + 20% synthetic serum supplement (SS;
Irvine Scientiﬁc; Santa Ana, CA), followed 10 min dilutions in
0.8 M glycerol and then 1.6 M glycerol + 0.2 M Sucrose. Individual
or paired blastocysts were loaded into and heat sealed in either
0.25 ml IMV straws or 0.3 ml CBS embryo straws. Blastocoele col-
lapsing was not performed on vitriﬁed blastocysts maintained in
ICE Me2SO-free vitriﬁcation solutions. With conventional SF, sur-
vival rates were classiﬁed as transferrable blastocysts possessing
>50% intact cells post-thaw. Alternatively, vitriﬁed blastocysts
were considered to have survived based on their osmotic respon-
siveness (i.e., cellular contraction and equilibration) to sucrose
Fig. 1. Preliminary data logger results of lS-VTF straws and ﬂexipettes (i.e., Stripper tip) were used to evaluate their separate and combined cooling rate potential in LN2 and
warming characteristics under room/ambient conditions. Removing the stripper tip from the straw and warming it in air did not signiﬁcantly improve its warming rate
compared to warming it by immersion of the straw in which it was contained. The straw in which it was contained warmed more rapidly than the contained stripper tip due
to thermal lag across the stripper tip wall. In all cases, an undesirable slowing in the warming between 100 C and 60 C was observed, raising concerns about potential
recrystallization and possible cellular damage.
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ﬁed blastocysts in our system was more of an all or none outcome
to the maintenance of cellular integrity. When blastocysts
possessed >5% pyknotic cells and failed to contract and/or
re-equilibrate in sucrose solutions they were considered as having
not survived.
All cryopreserved embryo transfer (CET) cycles involved hor-
mone replacement cycles using oral Estradiol (E2), E2 patches or
i.m. E2 valerate followed by i.m. Progesterone (P4; in oil, 50 mg
b.i.d., started when endometrial thickness wasP8 mm after docu-
mentation of serum P4 levels 61 ng/dl). All transfers were per-
formed 5 days after P4 supplement using transvaginal guidance
to speciﬁcally deposit the embryo(s) 1 cm from the fundus [1]
using a Sure View Wallace embryo replacement catheter
(Smiths Medical Ltd., Kent, UK). The ﬁrst blood test for b-hCG
was drawn 10 days post-embryo transfer, while clinicalpregnancies (CP) were documented by the presence of fetal cardiac
activity at the 7 week ultrasound. Implantation rates (IR) were cal-
culated by the number of conﬁrmed sacs divided by number of
transferred blastocysts. The ﬁnal determinant of success was the
live birth rate. In the validation of the clinical effectiveness of vit-
riﬁcation, all CET cycles (BL/SF, CBL/SF and VTF) from 2008 and
2009 were contrasted by retrospective analysis (Phase 3) and com-
pared to fresh embryo transfer outcomes. In addition, the overall
clinical efﬁcacy of lS-VTF application was further assessed over a
3 year period between 2009 and 2011 (Phase 4), and contrasted
to our Medical Director’s fresh IVF cycle data reported to the
Society for Assisted Reproductive Technology (SART). SART is an
afﬁliated sub-society of the American Society for Reproductive
Medicine (ASRM) who reports the annual IVF statistics/data of its
member clinics to the Center for Disease Control annually as man-
dated by the federal government.
Fig. 2. In frame A, pre-labeled CBS embryo straw awaits open-ended (right straw) within the conﬁnes of its sterile packaging during vitriﬁcation set-up. The central straw is
being reliably sealed in an automated Syms 1 sealer, with the completed weld seal seen on the straw to the left. Note that the tamperproof internalized labels can be different
colors and secured on different colored weighted ID rods. In 2B, the frozen lS-VTF straw is secured with heavy-duty surgical scissors just below the internal hydrophobic plug
separating the dual-colored identity label from the vitriﬁcation tip, which is safely maintained in sub 150 C conditions. For extraction and warming, the straw is lifted from
the LN2, cut in a horizontal position and then tilted downward to release the contents as per 2C. Frame 2C shows a vitriﬁed ﬂexipette, containing 3 ll of red dye, free-falling
from the opened CBS embryo straw into its target, a petri dish ﬁlled with warm medium to serve as a thaw bath. Note that a secondary, typical ﬂexipette (without dye) rests
securely against the dish edge while warming, prior to being attached to a Micro-Cap pipettor to gently evacuate contents into 1.0 M sucrose in a separate multi-well elution
dish.
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The vitriﬁcation procedure has been described in detail
previously [32,33] (Fig. 2). All handling procedures were performed
at room temperature (20–24 C) using a 3-step vitriﬁcation
solution addition and 5-step dilution procedure, as described in
detail elsewhere [32]. For vitriﬁcation, all oocytes and embryos
(day 1 and 3) were placed into V1 and V2 solutions for 5 min
and 2 min, respectively, and 5 min and 5 min for blastocysts.
Following V2 equilibration, embryos and oocytes were pipetted
into the ﬁnal V3 solution for 1–1.5 min, respectively, and loaded
into a 3 ll column in the ﬂexipette. The tip was simply removed
and wiped dry on sterile gauze, and then inserted completely into
the inner lumen of the open-ended straw before ﬁnal weld sealing
and direct placement into LN2 storage.
Prior to cooling, the outer CBS straws were heat sealed as
described in Fig. 2A. For warming, the identiﬁcation of a patient’s
colorized straw label (with the aseptic contents submerged in
LN2) was safely and effectively performed by grasping the
lS-VTF straw with large surgical scissors (Fig. 2B) just below the
internal plug. Once the ID was conﬁrmed, the straw was quickly
pulled up into ambient air and a ‘‘cut-tilt-tap’’ technique applied
(refer to YouTube video, ‘‘microSecure vitriﬁcation warming’’).
The straw was cut in a horizontal position while holding the
non-labeled end and then tilted downward (45–60 angle) over a
warm (37 C) 0.5 M sucrose bath, tapped gently and the vitriﬁca-
tion tip was allowed to free-fall directly into the 58 mm diameter
petri dish for rapid warming (Fig. 2C). Within 10 s, the ﬂexipette
was removed from the bath and its contents expelled into a
1.0 M sucrose solution. The cryoprotectants were then eluted from
the oocytes or embryos in a series of declining sucrose concentra-
tions (e.g., 1.0 M to 0.5 M to 0.25 M to 0.1 M; proprietary solutions:
T1–T4; 5 min/step) at room temperature (20–24 C) before a 5 min
isotonic equilibration in culture medium at 37 C, as described
elsewhere [32,33]. The routine thawing of slow frozen blastocysts
has been described previously [15].Pregnancy outcomes were evaluated by the determination of
+b-hCG levels, clinical pregnancy, implantation and live birth rates.
In Phase 3, the cryopreservation treatments were all compared to a
fresh blastocyst embryo transfer group with rate (%) differences
determined using Chi-square analysis.
Results
Phase 1: warming rate validation
In the validation of a modiﬁed warming procedure for lS-VTF, it
became clearly evident that the immediate submersion of the ﬂex-
ipette into a warm bath signiﬁcantly enhanced the warming rate
by approximately 600%, from 1114 C/min (Fig. 1) to a mean of
6233 C/min (Fig. 3), compared to preliminary measurements
under ambient air exposure (Fig. 1). More importantly, it elimi-
nated the biphasic pattern of warming previously observed, where
a signiﬁcant decline in warming rate was evident by 100 C with
a distinct shift seen between 60 C and 40 C (Fig. 1). Signiﬁcant
variation recorded in warming run 2 was due to a slight delay in
plunging of the tip into the warming bath. Overall the warming
rate for this sample was still more than 2-fold greater than the
cooling rate and, more importantly, the warming rate
above  90 C was just as rapid as the other samples. It is doubt-
ful that slower warming below 90 C would be harmful to the vit-
riﬁed oocytes and embryos. The calculated cooling rate of
1391 C/min was consistent with previous measurements. Thus,
we veriﬁed that the mean warming rate is 4.5-fold greater than
the cooling rate.
Phase 2: survival and developmental competence of abnormal human
embryos
Our initial observations of the applied effectiveness of lS-VTF
on oocytes, zygotes and embryos (Table 1), revealed a high level
of survival (95–100%) independent of the developmental stage
Table 1
Preliminary evaluation of the cellular survival of microSecure vitriﬁed human
embryos derived from immature eggs and abnormal zygotes.
Developmental
stage
No.
vitriﬁed
No.
recovered
No. survived (%)
**partial: P50%/
75%
No. complete
survival (%)
IVM MI/MII
Oocytes
21 21 20 (95%) 20 (95%)
Pronuclear* 43 43 42 (98%) 42 (98%)
Cleavage*
(6c–8c)
28 28 28/23
(100%/82%)
19 (68%)
Blastocyst* 39 39 39/39
(100%/100%)
37 (95%)
* All tested research embryos were deemed abnormal based on fertilization
assessments.
** Partial survival was based on the presence of pyknotic/degenerate cells, which
was less than 50% or 25% of the cellular mass.
Cooling /Warming Curves: I.C.E. oocyte solution,
Schiewe-Fahy Cooling/Warming Method
Fig. 3. Final data logger results of lS-VTF straws and ﬂexipettes combined for
cooling rate assessments in LN2 and the warming characteristics of the extracted
ﬂexipettes plunged directly into a warm (37 C) bath (Fig. 2C). The rapid cooling
rate remained consistent at 1214 C to 1528 C/min, whereas the direct warming of
the vitriﬁed ﬂexipette in a 37 C medium bath achieved a mean rate of 6233 C/min.
The 4-fold increase in the rate of warming over cooling alleviated the prior concerns
of recrystallization events occurring upon devitriﬁcation.
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able at routinely recovering its vitriﬁed contents, with all 131
oocytes and embryos successfully recovered (100%). Only the day
3 cleavage-stage embryos were susceptible to partial damage of
some blastomeres (Fig. 4D), with 68% and 82% maintaining com-
plete or P75% cellular integrity, respectively. The developmental
potential of these abnormal fertilized embryos to grow to the blas-
tocyst stage was assessed following vitriﬁcation. 8% of the zygotes
and 10% of the cleavage stage embryos developed to the blastocyst
stage, which was similar to the 12% blastulation rate observed in a
fresh control group of abnormal zygotes (n = 66 embryos).Phase 3: retrospective parallel clinical testing of cryopreserved human
blastocysts
The encouraging ﬁndings of Phase 2 allowed us to move
forward with the incorporation of vitriﬁcation into our routine
blastocyst cryopreservation program. The Phase 3 validation ﬁnd-
ings comparing pregnancy outcomes of good prognosis patients
(634 years old) having fresh embryo transfers (n = 283) to thecryopreserved embryo transfers (n = 136) over a 2 year period
(2008–2009), revealed a consistent trend of improvement in cry-
opreservation outcomes. Although no differences were observed
in total survival rates between treatments (89–92%; Table 2), as
deﬁned as a transferable embryo (>50% intact cellular mass), it is
clearly evident by pregnancy outcomes that survival differences
did exist. Finally, lS-VTF was validated to be the most effective
procedure at preserving the overall viability of blastocysts, with
no differences exhibited in live birth rates or the implantation
potential of the vitriﬁed embryos compared to fresh control
blastocysts.Phase 4: veriﬁcation of microSecure’s clinical effectiveness
The efﬁcacy and importance of lS-VTF in our clinical practice
has become increasingly obvious (Table 3). All aspects of preg-
nancy outcome assessment in women <38 years old (n = 209) were
comparable to expectations for fresh embryo transfer results
(Table 4). Surprisingly, vitriﬁed pregnancy outcomes were excep-
tionally high in the older age women (38–43 years old; n = 54),
with a mean live birth rate of 53.7%. In either case, the effective-
ness of lS-VTF was clearly proven. After modifying the warming
procedure, there was a general improvement in both survival and
pregnancy outcomes after 2009 (Table 3). Survival improved
(p < 0.05) from 86.4% to over 94%, with the exception of a small
group of older age women (n = 20; 88.5%) in 2010, which averaged
out after 2011 when survival in that group was 98.3%. Not unex-
pectedly, more spontaneous miscarriages were observed in the
older-aged patients (13%) than women 37 years old or younger
(4.7%).Conclusion
Our study has veriﬁed the clinical efﬁcacy of a non-commercial,
aseptic closed vitriﬁcation system called microSecure for human
embryos. This device offers an unparalleled combination of safety,
security, simplicity, reliability and repeatability between techni-
cians unavailable in commercial vitriﬁcation devices [33]. Only
the High Security Vitriﬁcation (HSV) straw (CryoBioSystems,
France) and VitriSafe device (IVF Distribution GmbH, Bregenz,
Austria) offer similar quality control advantages, but they do not
have internal labeling and require the additional pipetting of
embryos and oocytes onto a carrier surface which introduces tech-
nical variation. Of critical importance, this study has validated the
cryophysical properties of Me2SO-free metastable vitriﬁcation
solutions in the lS-VTF device during cooling and warming. The
cooling rate of our closed straw system (1214–1528 C/min) is con-
sistent with other reported closed straw devices [36,39] being
rapidly plunged directly into LN2. Knowing that post-vitriﬁcation
survival is dependent on warming rates relative to cooling rates
[29], it was critical for us to develop a warming strategy which
optimized the warming rate. This was achieved by removal of
the embryo/oocyte-containing vitriﬁed ﬂexipette from the external
straw just prior to rewarming and direct immersion of the ﬂex-
ipette into a warm sucrose solution using a cut-tilt-tap technique
[32], in contrast to ambient air exposure. In this way, we achieved
a >6000 C/min warming rate which was >4 times greater than the
cooling rate, thus greatly reducing concerns about devitriﬁcation
mediated recrystallization [10,40]. Seki and Mazur [36] demon-
strated the importance of warming rates over cooling rate in a
closed straw experimental model with mouse oocyte survival
being maximized with a warming rate of 2950 C/min when cool-
ing proceeded at 522 C/min or 1827 C/min. The use of a 0.5 M
sucrose solution for warming was a quality control measure, to
protect against the possible inadvertent expulsion of an embryo
Fig. 4. The post-vitriﬁcation survival of different developmental stages is depict as complete for human oocytes [A], 8-cell embryos [C] and a blastocyst [E], being
indistinguishable from fresh oocytes and embryos. The partial survival of cleavage-stage embryos [D], being >75%, is clearly shown by the darken presence of pyknotic
blastomeres. A few pyknotic blastomeres are also seen in a blastocyst [F, left side] on its upper pole, in contrast to the completely lysed blastocyst to its right. Furthermore, a
small percentage of oocytes do not survive warming and elution steps [B], as evidenced by the lack of cellular responsiveness to osmotic changes and/or the eventual
darkening/degeneration before or after isotonic equilibration.
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remains open-ended during vitriﬁcation. In the hundreds of warm-
ing procedures performed in this validation study, the latter inci-
dent was not observed. However, clinical application to-date has
on rare occasions discovered an apparent missing blastocyst safely
eluted in the sucrose bath, reminding us to adhere to standard
protocol to not load embryos or oocytes too close to the tip.
High levels of complete oocyte and embryo survival were
attained in all of our Phase 2 developmental treatments, beingconsistent with summarized results reported by Edgar and Gook
[9]. Although we did not fertilize oocytes in this experimental
phase, we subsequently conﬁrmed the clinical efﬁcacy of lS-VTF
in a randomized controlled trial (n = 13 donor egg recipients),
using a non-Me2SO, glycol based solution. Post-warming, all 122
mature oocytes were recovered, 106 survived (87%;
Fig. 4A and B), 87 two pronucleate zygotes were produced (81%
normal fertilization). Upon transfer of Day 3 or Day 5 embryos
(2.3 mean embryos/transfer; total: n = 30), 7 clinical pregnancies
Table 2
Optimizing blastocyst (BL) cryopreservation with microSecure vitriﬁcation (lS-VTF) versus conventional slow freezing without (BL/SF) or with pre-freeze blastocoele collapse
(CBL/SF) for cryopreserved embryo transfer cycles performed in 2008 and 2009.
Patient Grp/treatment BL Thawed BL-ET (%survived) No. of ET (lBL/pt.) Pregnancy outcomes
+b-hCG (%) Clin. preg (%) Live birth (%) Impl. rate (%)
634 year old
Control 0 605 283 (2.1) 215 (76%)a 198 (70%)a 181 (64%)a 274 (45%)a
BL/SF 124 114 (90%) 47 (2.4) 23 (49%)b 14 (30%)c 11 (23%)c 12 (11%)c
CBL/SF 148 136 (92%) 52 (2.4) 36 (70%)a 26 (56%)b 21 (40%)b 29 (21%)b
lS-VTF 98 87 (89%) 37 (2.4) 27 (73%)a 24 (65%)a 22 (59%)a 34 (39%)a
a,b,cDifferent superscripts within columns reveal differences (p < 0.05).
Abbreviations: BL-ET. – No. of blastocysts transferred; lBL/pt. – mean No. of BL transferred per patient; +b-hCG – No. positive pregnancy test; Clin. Preg (CP) – No. of clinical
pregnancies; Impl. Rate – No. blastocysts resulting in a fetal sac with a heart beat.
Table 3
Clinical outcome data of vitriﬁed ET cycles by age.
Age group Year No. thawed No. survived (%) No. of BL No. of Impl. No. of transfers (lBL/pt) No. of +b-hCG No. of CP (%) No. of LB (%)
<38 2009 140 121 (86.4) 119 38 (31.9) 50 (2.4) 34 (68.0) 27 (54.0) 25 (50.0)
Years 2010 169 159 (94.1) 159 68 (43.0) 80 (2.0) 59 (73.8) 50 (62.5) 46 (57.5)
Old 2011 140 135 (96.4) 132 68 (51.5) 79 (1.7) 59 (74.7) 51 (64.6) 47 (59.5)
Sub-total 449 415 (92.4) 410 174 (42.4) 209 (2.0) 152 (72.7) 128 (61.2) 118 (59.5)
38–43 2009 23 20 (87.0) 18 2 (11.1) 7 (2.6) 5 (71.4) 3 (42.9) 2 (28.6)
Years 2010 52 46 (88.5) 46 12 (26.0) 20 (2.3) 15 (75.0) 12 (60.0) 9 (45.0)
Old 2011 59 58 (98.3) 50 30 (60.0) 27 (1.9) 23 (85.2) 21 (77.8) 18 (66.7)
Sub-total 134 124 (92.5) 114 44 (38.6) 54 (2.1) 43 (79.6) 36 (66.7) 29 (53.7)
Overall Total 583 539 (92.4) 524 218 (42.0) 263 (2.0) 195 (74.0) 164 (62.0) 147 (56.0)
⁄2009 data was inﬂuenced by the original ambient air thawing protocol, changed to direct-rapid thaw in a warm Sucrose bath by early 2010.
⁄⁄100% recovery rates were attained.
⁄⁄⁄Survival was deﬁned as P95% intact cells and an embryo displaying overt osmotic changes and re-equilibration.
Abbreviations: No. of Impl. – No. of BL implanting; lBL/pt – mean No. of BL transferred per patient; No. of +b-hCG – No. of positive pregnancy tests; No. of CP – No. of clinical
pregnancies; No. of LB – No. of live births.
Table 4
Clinical outcome SART Data* of Fresh ET cycles by age.
2009 2010 2011 Total
<38 years old
No. of ET cycles 144 154 152 450
Live birth rate 48.4% 53.9% 50.0% 50.8%
Implantation rate 32.8% 38.7% 39.2% 37.0%
38–42 years old
No. of ET cycles 107 133 130 370
Live birth rate 21.1% 31.1% 29.4% 27.6%
Implantation rate 12.0% 14.7% 19.3% 15.5%
* Weighted values represent combined age grouping acquired from SART statistics
for the Southern California Center for Reproductive Medicine, Newport Beach, CA.
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babies [33]. The latter oocyte vitriﬁcation outcomes are compara-
ble to those reported with open device-EG/Me2SO systems
[5,6,25] and a closed system [25]. In Phase 2, the viability of vitri-
ﬁed embryos was partially conﬁrmed. Abnormal zygotes and
cleaved embryos following vitriﬁcation developed to the blastocyst
stage at a comparable rate to non-vitriﬁed (fresh) abnormal
zygotes. Although the day 3 cleavage-stage embryos only experi-
enced 68% completely intact cell survival, this ﬁnding was consis-
tent with the 74% occurrence reported by Balaban et al. [2] for
vitriﬁed day 3 embryos. In both cases, the overall survival of 95–
100% survival achieved was a signiﬁcant improvement over typical,
historic slow freezing success.
The retrospective analysis of our blastocyst freezing success in
Phase 3 revealed that our adoption of technical advances (i.e.,
pre-freeze blastocoele collapsing and then vitriﬁcation) signiﬁ-
cantly improved pregnancy outcomes. Although blastocystsappeared to survive conventional slow freezing fairly well, being
completely intact 60–70% of the time, it is apparent that signiﬁcant
harm to the trophectoderm layer seemingly impaired both
implantation and overall pregnancy success. In contrast, slow
frozen collapsed blastocysts (CBL/SF) effectively preserved the tro-
phectoderm, with +b-hCG outcomes being similar to lS-VTF and
the fresh control groups. However, the fewer clinical pregnancies
in CBL/SF treated embryos compared to lS-VTF suggests that there
may have been an impact on inner cell mass viability following
slow freezing. By incorporating pre-freeze blastocoele collapse
we apparently better sustained the functionality of the trophecto-
derm layer post-thaw, which led to greater implantation potential.
The positive effect of blastocoele collapse on survival and implan-
tation was consistent with other reports [14,39]. However, even
though a healthier trophectoderm led to greater implantation suc-
cess, the maintenance of clinical pregnancies was still reduced in
the CBL/SF treatment group, due to probable unnoticed cryoinjury
of the inner cell mass of these intact blastocysts. As blastocyst vit-
riﬁcation evolved, blastocoele collapse was found to be advanta-
geous by investigators using EG/Me2SO vitriﬁcation solutions
with open [23] and closed systems [20,39]. Yet, Stachecki and
coworkers [38] found their non-Me2SO, glycerol based VTF solu-
tion did not require physical collapse of the blastocoele cavity to
yield high survival rates and pregnancy outcomes. In fact, our
experience with lS-VTF using I.C.E. blastocyst vitriﬁcation solu-
tions yielded complete survival of the trophectodermal layer over
92% of the time, with the occasional appearance of non-viable,
pyknotic nuclei as described by Ebner et al. [8].
The increased intracellular concentration of cryoprotective
agents associated with vitriﬁcation appears to have improved
cryoprotection of the inner cell mass of blastocysts, producing
cryopreserved embryo transfer pregnancy rates approaching those
of good prognosis (634 y.o.) fresh blastocyst embryo transfers. It is
M.C. Schiewe et al. / Cryobiology 71 (2015) 264–272 271interesting to note that the level of pregnancy success we were
able to achieve in an aseptic, closed vitriﬁcation system using a
glycerol-based, non-Me2SO solution between 2009 and 2011
(n = 263 vitriﬁed embryo transfer cycles) was comparable to
another closed carrier system [20], only when they artiﬁcially
collapsed their blastocysts prior to vitriﬁcation in EG/Me2SO
solutions (2010–2012; n = 276 vitriﬁed embryo transfer cases). In
fact, when they did not collapse the blastocoele cavity they
observed similar overt survival of blastocysts (98.6–98.9%), but sig-
niﬁcantly reduced +b-hCG outcomes (50.7% vs. 75%), clinical preg-
nancies (43.2% vs. 63.4%), live birth rates (35% vs. 58.7%) and
implantation rates (32% vs. 46.7%). Similar pregnancy outcomes
and good survival rates (82–84%) with non-collapsed blastocysts
were recently exhibited in a prospective randomized study
showing no difference between an open or closed VitriSafe
(VitriMed, Austria) device [24]. However, several studies do indi-
cate that blastocoele collapse is useful to optimize a EG/Me2SO
vitriﬁcation protocol [14,20,23]. Our lS-VTF/I.C.E. system opti-
mized +b-hCG outcomes (74%), clinical pregnancies (62%), live
birth rates (56%) and implantation rates (42%) without the need
for pre-vitriﬁcation collapsing of the blastocoele cavity. This
phenomenon is likely attributed to the lower permeation rate of
glycerol having a sustained effect on water efﬂux at the time of
rapid cooling. The beneﬁt of the lS-VTF/I.C.E. blastocyst vitriﬁca-
tion system was particularly apparent in women P38 years old
who seem to beneﬁt from the use of their embryo(s) in a
non-hormonally stimulated CET cycle. Shapiro and coworkers
[37] showed that CET cycles provide optimum uterine receptivity
conditions to maximize implantation and pregnancy outcomes.
The impressive rise in live births we observed in 2011 (Table 3)
is partially attributed to our initial efforts to biopsy blastocysts
and subsequently cryo-store only euploid embryos. In either case,
CET pregnancy rates were appreciably higher than similar fresh
embryo transfer cycles.
Over a 4 year period, we successfully completed a validation–
veriﬁcation study that extensively documented the cryobiology
of a novel aseptic closed vitriﬁcation system for human oocytes
and embryos. lS-VTF has proven to be a clinically competent pro-
cedure worthy of worldwide ART industry acceptance. As a
non-commercialized, FDA compliant approach, lS-VTF offers a sig-
niﬁcant cost-savings over common marketed devices for oocyte
and embryo storage, and is a technically simple approach optimiz-
ing quality control considerations of labeling, weld sealing, aseptic
storage and user repeatability.Conﬂict of interest
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